Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics.
Ono M, Matsubara J, Honda K, Sakuma T, Hashiguchi T, Nose H, Nakamori S, Okusaka T, Kosuge T, Sata N, Nagai H, Ioka T, Tanaka S, Tsuchida A, Aoki T, Shimahara M, Yasunami Y, Itoi T, Moriyasu F, Negishi A, Kuwabara H, Shoji A, Hirohashi S, Yamada T. Ono M, et al. Among authors: sata n. J Biol Chem. 2009 Oct 16;284(42):29041-9. doi: 10.1074/jbc.M109.041749. Epub 2009 Aug 20. J Biol Chem. 2009. PMID: 19696023 Free PMC article.
Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer.
Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T. Matsubara J, et al. Among authors: sata n. Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):160-71. doi: 10.1158/1055-9965.EPI-10-0397. Epub 2010 Dec 8. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21148121
Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray.
Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, Sakuma T, Kuwabara H, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Shimahara M, Yasunami Y, Ino Y, Tsuchida A, Aoki T, Tsugane S, Yamada T. Murakoshi Y, et al. Among authors: sata n. Cancer Sci. 2011 Mar;102(3):630-8. doi: 10.1111/j.1349-7006.2010.01818.x. Epub 2010 Dec 28. Cancer Sci. 2011. PMID: 21199170 Free article.
Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray.
Matsubara J, Honda K, Ono M, Sekine S, Tanaka Y, Kobayashi M, Jung G, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Yamada T. Matsubara J, et al. Among authors: sata n. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2195-203. doi: 10.1158/1055-9965.EPI-11-0400. Epub 2011 Aug 9. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21828233 Free article. Clinical Trial.
Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.
Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, Ioka T, Tsuchida A, Shimahara T, Shimahara M, Yasunami Y, Kuwabara H, Sakuma T, Otsuka Y, Ota N, Shitashige M, Kosuge T, Büchler MW, Yamada T. Honda K, et al. Among authors: sata n. PLoS One. 2012;7(10):e46908. doi: 10.1371/journal.pone.0046908. Epub 2012 Oct 8. PLoS One. 2012. PMID: 23056525 Free PMC article.
Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S, Yamada T. Honda K, et al. Among authors: sata n. Sci Rep. 2015 Nov 9;5:15921. doi: 10.1038/srep15921. Sci Rep. 2015. PMID: 26549697 Free PMC article.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: sata n. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T. Yoneyama T, et al. Among authors: sata n. PLoS One. 2016 Aug 31;11(8):e0161009. doi: 10.1371/journal.pone.0161009. eCollection 2016. PLoS One. 2016. PMID: 27579675 Free PMC article. Clinical Trial.
351 results